The Modulatory Effects of Cannabidiol on Microglial Function and Receptor Expression in Epilepsy
Epilepsy, a chronic disorder characterized by abnormal brain cell activity leading to recurrent seizures, has recently seen increased and FDA‐approved usage of cannabidiol (CBD) as a treatment for intractable epilepsies. CBD, a non‐psychotropic component of Cannabis sativa, is reported to lessen the severity of experimentally induced seizures in animals and to suppress neuroinflammation in culture. This compound has been able to provide therapeutic options for the nearly 30% of patients who do not respond to traditional epilepsy medications. Although CBD has been shown to increase intracellular levels of anandamide, an endogenous cannabinoid, its mechanism of action is still poorly understood. Our lab has shown that microglia, the immune cells of the central nervous system (CNS), act as important mediators of seizure severity. The ability of microglia to modulate seizures has been associated with the activation of Toll‐like receptors (TLRs), which play important roles in pathogen recognition and inflammation. Microglia also contribute to neurogenic processes and synapse maturation, aiding in the formation of functional neuronal circuits. Our preliminary data suggest that CBD functions partially through microglia. We postulate that CBD modulates the activation of microglial cells in the brain during experimental epilepsy. In this study, we evaluate the effects of CBD on cell death, inflammation and microglial receptor expression in vitro and in vivo post seizure. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
The FASEB Journal - 33(2019), S1, Seite 804.6-804.6 |
| Beteiligte Personen: |
Victor, Tanya R. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© Federation of American Societies for Experimental Biology |
|---|
| Umfang: |
1 |
|---|
| doi: |
10.1096/fasebj.2019.33.1_supplement.804.6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY006400760 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY006400760 | ||
| 003 | DE-627 | ||
| 005 | 20230307161012.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2019 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1096/fasebj.2019.33.1_supplement.804.6 |2 doi | |
| 028 | 5 | 2 | |a FSB2_FSB2FASEBJ2019331SUPPLEMENT8046.xml |
| 035 | |a (DE-627)WLY006400760 | ||
| 035 | |a (WILEY)FSB2FASEBJ2019331SUPPLEMENT8046 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 570 |q ASE |
| 084 | |a 42.00 |2 bkl | ||
| 100 | 1 | |a Victor, Tanya R. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a The Modulatory Effects of Cannabidiol on Microglial Function and Receptor Expression in Epilepsy |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Federation of American Societies for Experimental Biology | ||
| 520 | |a Epilepsy, a chronic disorder characterized by abnormal brain cell activity leading to recurrent seizures, has recently seen increased and FDA‐approved usage of cannabidiol (CBD) as a treatment for intractable epilepsies. CBD, a non‐psychotropic component of Cannabis sativa, is reported to lessen the severity of experimentally induced seizures in animals and to suppress neuroinflammation in culture. This compound has been able to provide therapeutic options for the nearly 30% of patients who do not respond to traditional epilepsy medications. Although CBD has been shown to increase intracellular levels of anandamide, an endogenous cannabinoid, its mechanism of action is still poorly understood. Our lab has shown that microglia, the immune cells of the central nervous system (CNS), act as important mediators of seizure severity. The ability of microglia to modulate seizures has been associated with the activation of Toll‐like receptors (TLRs), which play important roles in pathogen recognition and inflammation. Microglia also contribute to neurogenic processes and synapse maturation, aiding in the formation of functional neuronal circuits. Our preliminary data suggest that CBD functions partially through microglia. We postulate that CBD modulates the activation of microglial cells in the brain during experimental epilepsy. In this study, we evaluate the effects of CBD on cell death, inflammation and microglial receptor expression in vitro and in vivo post seizure. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal. | ||
| 700 | 1 | |a Nissen, Jillian C. |4 aut | |
| 700 | 1 | |a Elmes, Matthew W. |4 aut | |
| 700 | 1 | |a Deutsch, Dale G. |4 aut | |
| 700 | 1 | |a Tsirka, Stella E. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The FASEB Journal |g 33(2019), S1, Seite 804.6-804.6 |w (DE-627)WLY005785006 |x 15306860 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2019 |g number:S1 |g pages:804.6-804.6 |g extent:1 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 42.00 |q ASE |
| 951 | |a AR | ||
| 952 | |d 33 |j 2019 |e S1 |h 804.6-804.6 |g 1 | ||